Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss pharmaceutical firm signed an exclusive agreement with Zealand Pharma to produce ...

For eligible patients, health care providers can send Wegovy prescriptions directly to NovoCare Pharmacy. Novo Nordisk is providing direct-to-patient delivery of Wegovy ® (semaglutide) through the ...

Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to patients paying cash, as it grapples with shifts to the competitive ...

Novo Nordisk (NVO) plans to study how its GLP-1 drugs marketed as Wegovy and Ozempic for obesity and diabetes can help tackle ...

Novo Nordisk is cutting the price of its weight-loss drug Wegovy to $499 per month for cash-paying customers who buy through its NovoCare Pharmacy. The discounted price is aimed at uninsured ...

The CEO of <strong>Novo Nordisk</strong> warned of the impact of tariffs on the pharmaceutical industry. Weight-loss drugs, including Ozempic and Wegovy, could cost ...